HARRISBURG – State Attorney General Tom Corbett Wednesday announced a $60 million stipulated judgment with Pfizer Inc., resolving a multi-state investigation into the company’s marketing and promotion of two pain relief and anti-inflammatory medications.
The investigation focused on the actions of Pfizer and another drug company, Pharmacia, which was purchased by Pfizer, who were accused of misrepresenting that Celebrex was safer and more effective than traditional medications such as Ibuprofen, Corbett said in a news release.
Pfizer also allegedly failed to disclose certain health risks related to Celebrex.
Corbett said investigators were also concerned about Pfizer’s alleged aggressive, deceptive and unlawful campaign to promote off-label uses for another similar drug, Bextra. Drug manufacturers are legally prohibited from marketing their products for off-label uses, he said.
Pennsylvania will receive nearly $2.5 million as a result of the settlement, Corbett said. The terms of the judgment would also prevent future deceptive marketing and promotions by Pfizer.